Home » Posts tagged 'quantum pharma'
Tag Archives: quantum pharma
BHP Billiton BHP benefited in 2017 from a substantial reduction in exceptional losses which fell from $6.4b in 2016 to $842m. as the Samarco dam failure in Brazil weighed less heavily on the company. The year to the 30th June turned out to be a very strong financial year with free cash flow at $12.b., the second highest on record and net debt down by 37%. On an underlying basis, EBITDA rise by 64%, basic earnings per share by 455% and attributable profit multiplied from $1.2b to $6.7b. Having laid the foundations over the past five years to improve return on capital and grow shareholder value, the momentum will continue into 2018 with volume growth of 7% expected, as well as further productivity gains.
Accordingly shareholders receive their reward with dividends for the year increased by 177% to a total of 83 cents per share.
Wood Group (John) plc WG had a mix of both robust and weaker performances across its businesses in the 6 months to the 30th June. Total revenue declined by 11% but profit was down by 86% and basic earnings per share by 89.0%. The interim dividend is increased cautiously by 3%.
Empresario Group EMR produced a record first half performance with revenue rising by 50% at constant exchange rates and adjusted profit before tax up by 24% or 12% at constant exchange rates. The company has successfully integrated its two acquisitions into the business and see them both offering further opportunities for growth.
Sareum Holdings SAR expects that profit for the year to 30th June and cash at the bank will be ahead of market expectation.
Proactis Holdings plc PHD expects to see a 31% rise in revenue for the year to 31st July, with EBITDA up 43% and profit before tax rising from 3.1m to 5.3m
Quantum Pharma plc QP Revenue for the half year to the 31st July rose by 13% following a strong performance from Niche Pharmaceuticals. Adjusted EBITDA rose by 23% and statutory operating prfit by 74% whilst net debt halved to 11.9m.
Bilby plc BILB With revenue doubling in the year to 31st March and gross profit rising from £6m. to £11.02m., Bilby has established itself as the largest gas contractor in London and the South East. However after various non underlying items, profit before tax fell from a restated £0.72m in 2016 to this years £0.06m. On an adjusted basis last years basic earnings per share of 5.34p has increased to 7.66p. The annual dividend is to be 2.2p per share compared to a restated 2.75p. per share for 2016.
Advanced Oncotherapy AVO announces another year of significant progress and development in the commercialisation of its next-generation technology in the treatment of cancer – LIGHT. Despite some challenges and obstacles during the year to the end of December, these have been overcome and the company looks forward to successfully executing the timelines that were outlined in March 2017. Since the year end, management has been strengthened and significant technical milestones have been reached. New finance has also been agreed and secured.
LPA Group LPA claims that the excellent levels of orders and sales announced at the AGM, has continued through the half year to 31st March. Profit before tax has risen from £782,000 to £976,000 on revenue up by 3.1% Diluted earnings per share are up from 5.34p to 6.81p per share. The interim dividend is to be raised by 5% to 1.05p per share.However despite those claims about the excellence of the order book, it stands at £22m., exactly where it was at half time, a year ago.
Quantum Pharma plc QP. announces the disposal of its homecare and dispensary business enabling it to focus on its Niche and Specials divisions and eliminate low margin turnover.The Niche & Specials divisions have been trading ahead of plan in the early months of the year and the outperformance here is expected to offset the majority of the loss from the division which is being disposed of.